How Innovation is Transforming India's Pharma Sector: NIH Veteran
Former NIH chief Elias Zerhouni paints an optimistic picture of India's pharmaceutical landscape, attributing its surge to innovation, vaccine dominance, and growing clinical expertise. Speaking from...
Former NIH chief Elias Zerhouni paints an optimistic picture of India's pharmaceutical landscape, attributing its surge to innovation, vaccine dominance, and growing clinical expertise. Speaking from Boston, he positions India as entering a pivotal growth phase. The India-US biotech partnership has matured, expanding from production to pioneering joint ventures. 'Companies like Lupin and Sun are everywhere now, and India is viewed through an innovative lens,' Zerhouni told IANS. India's iron grip on generics and APIs anchors global pharma, predominantly sourced from India and China. But Zerhouni stresses progression: Serum Institute's vaccine prowess has made India a linchpin in international health efforts. Central to this is India's knack for 'frugal innovation'—effective, affordable remedies that reach billions, a hallmark of its approach. COVID-19 exposed systemic weaknesses, forcing a hard look at health resilience. Lacking grand strategies, India and the US thrive on private sector synergy and incentives. Drawing from experience, Zerhouni reminisced about navigating red tape with leaders like Manmohan Singh. Clinical trials in India show promise but require refined regulations and facilities. Investment diversification from China boosts India's medtech and research collaborations. Amid US affordability crises, India's equitable health focus shines. AI boosts research speed, yet awaits breakthrough potential. As biotech globalizes, Zerhouni welcomes India's role: 'What matters is healing patients, regardless of source.' This vision underscores a collaborative, patient-centric future.